AI that is using next-generation
Posted: Thu Feb 13, 2025 5:10 am
Under the terms of the agreement, Stemline will provide Insilico with an upfront payment of $20 million. The total value of the transaction is more than $550 million, including all development, regulatory and commercial milestones, with tiered royalties to follow.
Prior to this collaboration, Menarini Group and Insilico signed an exclusive licensing agreement in January 2024 for MEN2312: MEN2312 is an innovative small molecule drug for the treatment of breast cancer and other oncology indications.
MEN2312 Introduction
Designed by Insilico's R&D team with the assistance of its end-to-end pharmaceutical generation AI platform, MEN2312 can block endocrine receptors (ER) at the transcriptional level, giving it the potential to usa student data overcome resistance to endocrine therapy due to mutations or ligand-independent constitutive activation of ER. In preclinical studies, this molecule has been shown to have a potent inhibitory effect on KAT6 in a variety of CDX and PDX models, with good efficacy and high safety.
About Menarini Group
Menarini Group is a leading international pharmaceutical and diagnostics company with revenues in excess of US$ 4.7 billion and over 17,000 employees. Menarini focuses on developing products in areas of unmet therapeutic need, including cardiology, oncology, respiratory medicine, gastroenterology, infectious diseases, diabetes, inflammation and analgesia. Menarini has 18 production sites and 9 R&D centers, and its products are sold in 140 countries around the world. For more information, please visit.
About Insilico Medicine
Insilico Medicine is a global clinical-stage biotechnology company driven by generative AI systems to connect biology, chemistry, and clinical trial analysis. The company has developed an AI platform that uses deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover new targets and generate novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative medicines for the treatment of cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases and aging-related diseases.
Prior to this collaboration, Menarini Group and Insilico signed an exclusive licensing agreement in January 2024 for MEN2312: MEN2312 is an innovative small molecule drug for the treatment of breast cancer and other oncology indications.
MEN2312 Introduction
Designed by Insilico's R&D team with the assistance of its end-to-end pharmaceutical generation AI platform, MEN2312 can block endocrine receptors (ER) at the transcriptional level, giving it the potential to usa student data overcome resistance to endocrine therapy due to mutations or ligand-independent constitutive activation of ER. In preclinical studies, this molecule has been shown to have a potent inhibitory effect on KAT6 in a variety of CDX and PDX models, with good efficacy and high safety.
About Menarini Group
Menarini Group is a leading international pharmaceutical and diagnostics company with revenues in excess of US$ 4.7 billion and over 17,000 employees. Menarini focuses on developing products in areas of unmet therapeutic need, including cardiology, oncology, respiratory medicine, gastroenterology, infectious diseases, diabetes, inflammation and analgesia. Menarini has 18 production sites and 9 R&D centers, and its products are sold in 140 countries around the world. For more information, please visit.
About Insilico Medicine
Insilico Medicine is a global clinical-stage biotechnology company driven by generative AI systems to connect biology, chemistry, and clinical trial analysis. The company has developed an AI platform that uses deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover new targets and generate novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative medicines for the treatment of cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases and aging-related diseases.